Elevation Oncology, Inc. (ELEV)
Largest Insider Buys in Sector
ELEV Stock Price History Chart
ELEV Stock Performance
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Insider Activity of Elevation Oncology, Inc.
Over the last 12 months, insiders at Elevation Oncology, Inc. have bought $0 and sold $0 worth of Elevation Oncology, Inc. stock.
On average, over the past 5 years, insiders at Elevation Oncology, Inc. have bought $26M and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 187,500 shares for transaction amount of $3M was made by Aisling Capital IV, LP (10 percent owner) on 2021‑06‑29.
List of Insider Buy and Sell Transactions, Elevation Oncology, Inc.
| 2022-05-25 | Sale | 702,737 3.1622% | $4.12 | $2.9M | -69.80% | |||
| 2021-06-29 | 10 percent owner | 187,500 22.5074% | $16.00 | $3M | -56.00% | |||
| 2021-06-29 | 10 percent owner | 625,000 75.0247% | $16.00 | $10M | -56.00% | |||
| 2021-06-29 | 10 percent owner | 312,500 37.5123% | $16.00 | $5M | -56.00% | |||
| 2021-06-29 | 10 percent owner | 250,000 30.0099% | $16.00 | $4M | -56.00% | |||
| 2021-06-29 | 250,000 30.0099% | $16.00 | $4M | -56.00% |
Insider Historical Profitability
| Aisling Capital IV, LP | 10 percent owner | 2834910 4.7963% | $0.55 | 1 | 0 | <0.0001% |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 2608167 4.4126% | $0.55 | 1 | 0 | <0.0001% |
| Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2370142 4.0099% | $0.55 | 1 | 0 | <0.0001% |
| Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2307642 3.9042% | $0.55 | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2233168 3.7782% | $0.55 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Farallon Capital | $19.94M | 7.11 | 3.89M | New | +$19.94M | 0.14 | |
| Point72 Asset Management | $17.28M | 6.17 | 3.37M | New | +$17.28M | 0.03 | |
| Tang Capital Management, LLC | $15.7M | 5.6 | 3.06M | -16.57% | -$3.12M | 0.06 | |
| Balyasny Asset Management Llc | $15.67M | 5.59 | 3.06M | New | +$15.67M | 0.04 | |
| Aisling Capital Management LP | $14.54M | 5.19 | 2.83M | 0% | +$0 | 4.98 |